Proteolysis-targeting chimera (PROTAC) and other targeted protein degradation (TPD ... However, the power of PROTACs lies in the engagement of E3 ligases, and currently, less than two percent of the ...

In the case of a PROTAC, this binding involves an E3 ligase. Figure 1: An illustration from Arvinas showing the mechanism of proteolysis-targeting chimeras (PROTACs). Ultimately, the disease ...

Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study assessed vepdegestrant against AstraZeneca’s hormone med Faslodex in ...

Humanwell Healthcare (Group) Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 ...

A PROTAC is a heterobifunctional molecule that can bind both a target protein and an E3 ubiquitin ligase to facilitate the formation of a ternary complex, leading to ubiquitination and ultimate ...

Our group's research efforts aim to uncover novel cancer treatments and centre around three main themes: PROTAC, Molecular Glue Degraders, and novel E3 ligases. My earlier research in PROTAC ...